Omega-3 study for movement disorder pulled before start
NCT ID NCT00621634
First seen May 14, 2026 · Last updated May 22, 2026 · Updated 2 times
Summary
This study aimed to see if high doses of an omega-3 fatty acid called DHA could reduce involuntary movements in people with tardive dyskinesia, a side effect of long-term antipsychotic medication. The plan was to give 40 adults either DHA capsules or a placebo for 12 weeks and measure changes in movement. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TARDIVE DYSKINESIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Douglas Mental Health University Institute
Montreal, Quebec, H4H 1R3, Canada
-
Notre-Dame Hospital/CHU Montreal
Montreal, Quebec, H2L 4M1, Canada
Conditions
Explore the condition pages connected to this study.